This Harvard Medical School Continuing Education video examines these key questions: How do immune checkpoint inhibitors (ICIs) work, and what impact have they had on metastatic cancer survival rates? What are the applications for ICIs in early lines of cancer therapy?
Kerry Reynolds, MD, an oncologist at Massachusetts General Hospital reviews immune cell activation and checkpoint mechanisms. FDA-approved immune checkpoint inhibitors are listed. Current uses of ICI therapies including single-agent and combination therapies are discussed, and early and late-stage cancer types where ICIs are being applied are reviewed.
This video was peer reviewed by Dr. Jonathan Salik, TMD, MHPEd, Instructor of Medicine, Massachusetts General Hospital; and Dr. Sugantha Sundar, MD, Assistant Professor of Anesthesia, Beth Israel Deaconess Medical Center, to validate the quality and accuracy of the content. It was edited by affiliate physicians of Harvard Medical School, Arielle J Medford, MD, Senior Medical Oncology Fellow, Dana-Farber Cancer Institute and Anna Handorf, MD, Research Fellow in Pediatrics, Massachusetts General Hospital .
00:00 | Introduction
00:53 | Immunology review
02:18 | FDA-approved immune checkpoint inhibiting drugs
03:40 | Current uses of ICI therapies
05:04 | Summary
This video was peer reviewed by Dr. Jonathan Salik, TMD, MHPEd, Instructor of Medicine, Massachusetts General Hospital; and Dr. Sugantha Sundar, MD, Assistant Professor of Anesthesia, Beth Israel Deaconess Medical Center, to validate the quality and accuracy of the content. It was edited by affiliate physicians of Harvard Medical School, Arielle J Medford, MD, Senior Medical Oncology Fellow, Dana-Farber Cancer Institute, and Anna Handorf, MD, Research Fellow in Pediatrics, Massachusetts General Hospital.
References:
Immune Checkpoint Inhibitors: a new cancer treatment. bpacnz. March 21, 2018. bpac.org.nz/2018/checkpoint.aspx
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264. Published 2012 Mar 22. doi:10.1038/nrc3239
Haslam A, Gill J, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs. JAMA Netw Open. 2020;3(3):e200423. Published 2020 Mar 2. doi:10.1001/jamanetworkopen.2020.0423
Notice: At this time, the content in this video is not accredited.
- Cancer Immune Checkpoint Inhibitors ( Download)
- Immune Checkpoint Inhibitors ( Download)
- Immune Checkpoint Inhibitors, The Next Generation Cancer Therapy - Creative Biolabs ( Download)
- Immune Checkpoint Blockade in Cancer Therapy ( Download)
- Immunotherapy using checkpoint inhibitors (subtitles) ( Download)
- Introduction to Immune Checkpoint Inhibitor (ICI) Immunotherapy ( Download)
- Immune Checkpoint Inhibitors ( Download)
- What are Immune Checkpoints ( Download)
- Immune Checkpoint Blockade in Cancer Therapy by Dr. Jim Allison ( Download)
- Checkpoint Inhibitors: Taking the Brakes Off the Immune System ( Download)
- Cancer immunotherapy | The PD-L1 pathway ( Download)
- PD-L1/PD-1 Pathway: A Security Checkpoint ( Download)
- What are 'checkpoint' immunotherapy drugs | Immunotherapy | Cancer Research UK ( Download)
- Limitations in immune checkpoint inhibitors in treating gastric cancer ( Download)
- Checkpoint Inhibitors | How do they works as a cancer treatment | Cancer Research UK ( Download)
